【科济药业-B(02171.HK):国药监局受理舒瑞基奥仑赛注射液新药上市申请用于治疗晚期胃╱食管胃结合部腺癌】智通财经

智通财经
26 Jun
【科济药业-B(02171.HK):国药监局受理舒瑞基奥仑赛注射液新药上市申请用于治疗晚期胃╱食管胃结合部腺癌】智通财经APP讯,科济药业-B(02171.HK)发布公告,中国国家药品监督管理局(NMPA)已受理舒瑞基奥仑赛注射液(产品编号:CT041,一种靶向Claudin18.2的自体CAR-T细胞产品)的新药上市申请(NDA),用于治疗Claudin18.2表达阳性、至少二线治疗失败的晚期胃╱食管胃结合部腺癌(G/GEJA)患者。此次递交的NDA主要是基于一项在中国开展的开放标签、多中心、随机对照的确证性II期临床试验(CT041-ST-01, NCT04581473)结果。相关数据已在《The Lancet》和2025年美国临床肿瘤学会 (ASCO)年会上正式公布。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10